Share this video  

SITC 2022 | Decreasing the risk of immunotherapy-related kidney damage

Shruti Gupta, MD, Brigham and Women’s Hospital, Boston, MA, comments on reducing the risk of acute kidney injury in patients receiving checkpoint inhibitors. For patients who have lower kidney function and existing immune adverse advents, further monitoring is needed to detect any kidney damage. Replacing proton pump inhibitors, which have additionally been linked to kidney injury, with H2 blockers is another potential strategy. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.